0001104659-19-013869.txt : 20190311 0001104659-19-013869.hdr.sgml : 20190311 20190311164804 ACCESSION NUMBER: 0001104659-19-013869 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190305 FILED AS OF DATE: 20190311 DATE AS OF CHANGE: 20190311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Canute Scott A CENTRAL INDEX KEY: 0001303416 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12104 FILM NUMBER: 19672830 MAIL ADDRESS: STREET 1: FLEXION THERAPEUTICS, INC. STREET 2: 10 MALL ROAD, SUITE 301 CITY: BURLINGTON STATE: MA ZIP: 01803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOMEDICS INC CENTRAL INDEX KEY: 0000722830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 611009366 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 AMERICAN RD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 BUSINESS PHONE: 9736058200 MAIL ADDRESS: STREET 1: 300 AMERICAN ROAD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 4 1 a4.xml 4 X0306 4 2019-03-05 0 0000722830 IMMUNOMEDICS INC IMMU 0001303416 Canute Scott A C/O IMMUNOMEDICS, INC. 300 THE AMERICAN ROAD MORRIS PLAINS NJ 07950 1 0 0 0 Stock Option (right to buy) 16.96 2019-03-05 4 A 0 79818 0 A 2026-03-05 Common Stock, par value $0.01 per share 79818 79818 D Stock Option (right to buy) 16.35 2019-03-08 4 A 0 22854 0 A 2026-03-08 Common Stock, par value $0.01 per share 22854 22854 D The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan. The stock options vest in full upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act. /s/ Scott Canute 2019-03-11